Clopidogrel prescribing and concordance with the Pharmaceutical Benefits Scheme in hospital patients

Background: Clopidogrel is used for the secondary prevention of cerebrovascular and cardiovascular events. Clopidogrel has a similar safety profile to low-dose aspirin but is considerably more expensive. Clopidogrel is subsidised for restricted indications via the Pharmaceutical Benefits Scheme (PBS). Aim: To examine c1opidogrel prescribing in hospital; and to identify patients discharged on clopidogrel according to PBS criteria. Method: Cross-sectional evaluation of patients started on clopidogrel (July 2006 to June 2007) at the Royal Darwin and Royal Hobart Hospitals.Clopidogrel prescribing was examined and the indication for discharge on c1opidogrel was documented. The primary outcome was concordance between clopidogrel use and PBS criteria. Results: Data were collected for 385 patients. 54% of patients from the Royal Darwin Hospital and 39% of patients from the Royal Hobart Hospital discharged on c1opidogrel met PBS criteria.The main reason for noncompliance with the PBS was absenceof a history of cardiovascularor cerebrovascularevents while on low-dose aspirin and an absence of contraindications to aspirin at the time of c1opidogrel prescribing. Conclusion: Although c1opidogrel prescribing at the hospitals was often not in accordance with PBS criteria, in most cases prescribing was based on the available evidence.